InvestSMART

Paradigm Biopharmaceuticals Limited (ASX:PAR)

ALERT: Price-sensitive ASX Announcement for PAR
Current share price for PAR : $0.155 -0.02 (-11.43%)+
Announcement
Release
30 Apr 2026 8:13AM
Price at Release
$0.175
Full Release
download
Summary
Paradigm Biopharmaceuticals Ltd announced that its Phase 3 PARA_OA_012 clinical trial will continue following a successful Data Safety Monitoring Board (DSMB) safety review of the first 20% of participants. The review confirmed the safety profile of the trial, which evaluates injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis. Additionally, the first clinical trial site in Moldova has been activated to support the final phase of recruitment. This expansion is strategically aimed at accelerating participant enrolment to meet the target of 466 participants. The trial's interim analysis is scheduled for August 2026. Paradigm's Chief Medical Officer, Dr. Donna Skerrett, highlighted the importance of the DSMB review and the activation of additional sites in maintaining the trial's momentum.
Key Points
  • Phase 3 OA Trial continues after DSMB 20% Safety Review.
  • Moldova site activated to support the final recruitment phase.
  • The trial is targeting 466 participants and is progressing towards the 100% recruitment milestone.
  • Interim analysis is planned for approximately August 2026.
  • Dr. Donna Skerrett emphasizes the strategic progress in the trial's execution.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.